A retrospective population-based cohort study from Hong Kong has suggested that the cardiovascular safety of calcium supplementation was not supported for people with established cardiovascular disease (CVD), reports MedPage Today.
The researchers wrote in the Journal of the American Heart Association that among those prescribed calcium supplementation, there was an increased risk of recurrent adverse CVD events relative to controls (184.9 vs 167.5 events per 1 000 person-years, HR 1.10, 95% CI 1.07-1.14) in a propensity score-matched analysis.
Notably, the excess risk was observed for calcium supplementation by itself (HR 1.21, 95% CI 1.17-1.25) and not with combination calcium-vitamin D (HR 0.97, 95% CI 0.93-1.01), according to Ching-Lung Cheung, PhD, of the University of Hong Kong, and colleagues.
“Given the increased risk of CVD recurrence, caution should be exercised in prescribing or using calcium supplements in patients with CVD. Our observational results, consistent with meta-analyses, suggest that a combination of calcium and vitamin D supplementation is less concerning,” the study authors wrote.
“Importantly, most randomised controlled trials evaluating calcium supplements were not specifically designed or adequately powered to evaluate cardiovascular outcomes, particularly in individuals with established CVD,” they noted.
Calcium supplements are commonly used to treat or prevent calcium deficiency, which can lead to osteoporosis. Meanwhile, the relationships between calcium intake and cancer, CVD, weight management, dementia, and other conditions have been more controversial.
“The connection between calcium supplementation and the recurrence of CVD events seems plausible, as circulating calcium plays an important role in vascular and cardiovascular health. Studies have demonstrated that circulating calcium levels directly contribute to the development of coronary artery calcification and aortic calcification, both of which are strongly related to recurrent CVD,” said Cheung and colleagues.
It is also plausible that the combination of calcium with vitamin D mitigates the adverse effects of calcium.
“In animal models, vitamin D has been shown to regulate cholesterol efflux and macrophage polarisation and inflammatory process via vitamin D receptor in vessel walls,” they added, and correcting the vitamin D deficiency prevalent in Asian populations could improve CVD outcomes even for users of calcium.
“Furthermore, calcium supplements require vitamin D to be absorbed into bones: whether the different degree of absorption results in heterogeneous mineral metabolism in coronary arteries warrants future investigation," they suggested.
For their study, Cheung and colleagues relied on electronic hospital records for information on individuals aged ≥40 newly diagnosed with CVD in 2006-2015 in Hong Kong.
People prescribed oral calcium supplements (e.g., calcium carbonate, calcium lactate, calcium gluconate) and calcium supplements with vitamin D (either calcitriol or vitamin D2/D3 prescribed concurrently) made up the treatment group (n=38,586). Patients who had never been prescribed calcium supplements were the controls (n=192,460).
From propensity score matching, investigators were left with a matched cohort of 17 720 patients in each study arm. This cohort had an average age of 77 and were 58.2% women. The prevalence of diabetes was 30.6%, and osteoporosis was around 5%.
Antiplatelet use came close to 80%, and just more than half of the patients were on lipid-lowering agents.
The study had a total follow-up time of 102 969.6 person-years.
Individual recurrent CVD endpoints supported a disadvantage for calcium users:
• Acute myocardial infarction: HR 1.10 (95% CI 1.03-1.18)
• Stroke: HR 1.06 (95% CI 1.01-1.10)
• Coronary heart disease: HR 1.09 (95% CI 1.05-1.13)
In particular, men prescribed calcium had a pronounced association with recurrent CVD events (HR 1.15, 95% CI 1.09-1.20) compared with women (HR 1.07, 95% CI 1.03-1.11).
Besides recurrent CVD events, there was also a greater likelihood of CVD-related hospitalisation or accident and emergency department attendance in the calcium supplementation group (HR 1.16, 95% CI 1.13-1.20).
However, the observational study left room for unobserved residual confounding, the researchers cautioned.
“Additionally, the estimated risk may be biased toward the null by exposure misclassification from the potential OTC [over-the-counter] calcium supplement use. OTC use is more likely to occur in the controls than in the treatment group, thus leading to an underestimation,” the authors noted.
They also acknowledged that vitamin D deficiency is prevalent among East Asians, who also tend to have lower average dietary calcium intake.
Study details
Association between calcium supplementation and recurrence of cardiovascular events in patients with cardiovascular disease: a population‐based cohort study
Xiaowen Zhang, Kathryn Choon‐Beng Tan, Annie Wai‐Chee Kung et al.
Published in JAHA on 9 April 2026
Abstract
Background
The cardiovascular safety of calcium supplements in individuals with major cardiovascular disease (CVD) remains unclear. This study investigated the association between calcium supplementation and the risk of CVD recurrence in patients with established CVD.
Methods
A retrospective population‐based study was conducted in Hong Kong of individuals aged ≥40 years newly diagnosed with CVD from January 1, 2006, to December 31, 2015. The treatment group consisted of patients with CVD prescribed calcium supplements, while the control group consisted of those who never prescribed calcium supplements from January 1, 2005, to December 31, 2020. Propensity score matching and Cox proportional hazard models were adopted to balance the baseline characteristics and estimate hazards ratios (HRs) for CVD recurrence.
Results
The matched cohort included 17 720 patients with CVD in each arm. Calcium supplementation was associated with an increased risk of recurrence of adverse CVD events (HR, 1.10 [95% CI, 1.07–1.14]) and CVD‐related hospitalisation or accident and emergency department attendance (HR, 1.16 [95% CI, 1.13–1.20]). Calcium‐only supplementation had higher CVD recurrence risk (HR, 1.21 [95% CI, 1.17–1.25]) than the combination of vitamin D (HR, 0.97 [95% CI, 0.93–1.01]), and a more pronounced association was observed in men (HR, 1.15 [95% CI, 1.09–1.20]) than women (HR, 1.07 [95% CI, 1.03–1.11]).
Conclusions
In patients with major CVD, calcium supplementation is associated with an increased risk of CVD recurrence, particularly with calcium‐only use and in men. Caution should be exercised when prescribing or using calcium supplements among patients with CVD.
MedPage Today article – Further Doubt on Heart-Healthiness of Calcium Supplements (Open access)
See more from MedicalBrief archives:
Researchers confirm vitamin D link in CVD risk reduction
Vitamin D supplements do not reduce cardiovascular risk
Calcium supplements ‘do not’ compromise women’s heart health
Meta-analysis: No cardiovascular benefits to dietary supplements except vitamin B